Bioverativ Inc logo

BIVV - Bioverativ Inc News Story

$104.98 0.3  0.0%

Last Trade - 08/03/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £829.0m
Position in Universe th / 6846

BRIEF-Bioverativ Announces First Patient Dosed In Phase 3 Study Of BIVV009 For Cold Agglutinin Disease Treatment

Tue 6th March, 2018 12:35pm
March 6 (Reuters) - Bioverativ Inc  BIVV.O :
    * BIOVERATIV ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 STUDY
OF
BIVV009 FOR TREATMENT OF COLD AGGLUTININ DISEASE

Source text for Eikon:  ID:nBw5J4G4Na 
Further company coverage:  BIVV.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.